ArticleInternational journal of hematology2013

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Yoo Jin Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.